Highest-materiality recent filing
Habib J. Dable, Susan Moran, and Robert More elected Class II directors for three-year terms.
Tyra Biosciences Q1 net loss $39.3M; cash $383.5M; SURF302 data August 2026
Net loss $39.3M vs $28.1M YoY; R&D expenses $33.5M (+34%) driven by dabogratinib trials.
Tyra Biosciences expands board to ten, appoints Habib J. Dable as Class II director
Board increased from nine to ten members; Dable appointed effective April 16, 2026, with term expiring at 2026 annual meeting.
Tyra Biosciences designates VP Finance Julia Rueb as principal accounting officer
Julia Rueb (VP Finance) appointed principal accounting officer effective April 1, 2026, succeeding CFO Alan Fuhrman.
Tyra Biosciences raises $126M via block sale of 4M shares at $31.50 each
Sold 4M common shares at $31.50/share to a large investment management firm for $126M gross proceeds.
Tyra Biosciences reports FY2025 net loss of $119.9M; cash $256M, outlines dabogratinib 3x3 strategy
Q4 2025 net loss $33.8M vs $25.6M; FY net loss $119.9M vs $86.5M; R&D spend rose to $102.9M.
Tyra Biosciences appoints Bhavesh Ashar as COO; Bensen becomes Chief Discovery Officer
Bhavesh Ashar appointed COO effective Dec 1, 2025; Daniel Bensen moved to Chief Discovery Officer.
Tyra Biosciences Q3 net loss $29.9M; cash $274.9M; dabogratinib trials on track
Cash, equivalents, and marketable securities of $274.9M as of Sep 30, 2025; runway through at least 2027.
Tyra Biosciences doses first child in Phase 2 achondroplasia study of dabogratinib
First child dosed in BEACH301 Phase 2 study of dabogratinib (formerly TYRA-300) for achondroplasia.
Tyra Biosciences Q2 2025 cash $296.3M; dosed first patient in SURF302 NMIBC trial
Cash, cash equivalents and marketable securities of $296.3M as of June 30, 2025; runway through at least 2027.
SURF302 open-label Phase 2 study of TYRA-300 in FGFR3-altered low-grade IR NMIBC; up to 90 participants at US sites.
Tyra Biosciences stockholders elect three Class I directors and ratify EY as auditor
Todd Harris, Adele Gulfo, and S. Michael Rothenberg elected as Class I directors for three-year terms.
Tyra Biosciences Q1 net loss $28.1M; cash $318.9M; BEACH301 achondroplasia study open
Net loss $28.1M vs $18.2M in Q1 2024; R&D expense $25.0M (up 45% YoY) driven by clinical start-up costs.
Tyra Biosciences reports $86.5M net loss for 2024; cash runway through 2027; three INDs cleared
Cash, equivalents, and marketable securities $341.4M at YE 2024 (up from $203.5M), providing runway through at least 2027.
Tyra Biosciences appoints Adele M. Gulfo to board; Nina Kjellson resigns
Nina Kjellson resigned from board and Compensation Committee effective Jan 29, 2025, not due to disagreement.
Tyra Biosciences Q3 net loss $24M; cash $360M; positive interim TYRA-300 mUC data
Net loss $24.0M in Q3 2024 vs $21.2M in Q3 2023; R&D expense $22.7M, up from $19.3M.
Tyra Biosciences receives FDA clearance for Phase 2 trial of TYRA-300 in achondroplasia
FDA cleared IND for TYRA-300 Phase 2 trial (BEACH301) in children with achondroplasia ages 3-10.
Tyra Biosciences reports interim TYRA-300 data: 54.5% confirmed PR in FGFR3+ mUC at ≥90 mg QD
As of Aug 15, 2024, 41 patients enrolled in SURF301 Phase 1; 6/11 (54.5%) FGFR3+ mUC patients at ≥90 mg QD achieved confirmed partial response, 3 ongoing.
Tyra Biosciences to exchange 3M shares for pre-funded warrants with Boxer Capital, RA Capital
Boxer Capital exchanges 2M shares, RA Capital exchanges 1M shares of common stock.
Q2 net loss $18.7M ($13.3M in Q2 2023); R&D $18.0M; cash $373.8M, runway through at least 2026.
Tyra Biosciences shareholders approve officer exculpation amendment to charter
Amendment eliminates personal liability of officers for monetary damages for breach of fiduciary duty under Delaware law.
Tyra Biosciences Q1 net loss $18.2M; cash $382.5M; TYRA-300 on track for 2H24 milestones
Net loss of $18.2M in Q1 2024 vs $11.9M in Q1 2023; R&D expenses $17.2M.
Tyra Biosciences appoints Drs. Moran and Rothenberg to Board; Dr. Chen resigns
Isan Chen resigned from Board and Compensation Committee effective May 7, 2024, with no disagreement.
Tyra Biosciences reports FY 2023 net loss $69.1M; $403.5M cash after $200M PIPE
Q4 2023 net loss $22.8M vs $12.9M; FY net loss $69.1M vs $55.3M.
Tyra Biosciences announces $200M private placement led by RA Capital at $13.01/share
Gross proceeds of approximately $200 million from sale of ~15.4 million shares/pre-funded warrants at $13.01 per share.
FDA grants Rare Pediatric Disease Designation to Tyra Biosciences' TYRA-300 for achondroplasia
FDA granted Rare Pediatric Disease Designation to TYRA-300, an oral FGFR3 inhibitor, for achondroplasia.
First patient dosed in SURF201 Phase 1 study of TYRA-200 for FGFR2-altered cholangiocarcinoma and advanced solid tumors.
Tyra Biosciences reports Q3 net loss $21.2M; cash $215.7M; advances TYRA-300 and TYRA-200 trials
Q3 2023 net loss $21.2M vs $12.5M YoY; R&D expenses $19.3M (prior $10.9M).
Board approved amended bylaws effective Oct 26, 2023.
Tyra Biosciences Q2 net loss $13.3M; orphan drug designation for TYRA-300 in achondroplasia
Net loss $13.3M vs $15.1M Q2 2022; cash & equivalents $232.4M as of June 30.
Tyra Biosciences stockholders elect three Class II directors, ratify E&Y as auditor
Stockholders elected Isan Chen (37.3M for), Gilla Kaplan (37.6M for), and Robert More (37.6M for) as Class II directors to serve until 2026.
Tyra Biosciences Q1 net loss $11.9M, cash $241.7M; programs advance
Net loss $11.9M vs $14.8M YoY; R&D expense $10.4M, G&A $3.9M.
Q4 2022 net loss $12.9M vs $9.9M in Q4 2021; full year net loss $55.3M vs $26.3M.
TYRA-300 increased body length by 17.6% in FGFR3 Y367C/+ mice (p<0.0001); femur +24.4%, tibia +38.3%, L4-L6 +23.9%.
Tyra Biosciences doses first patient in Phase 1/2 SURF301 study of TYRA-300
First patient dosed in SURF301 Phase 1/2 study of TYRA-300 for FGFR3+ advanced solid tumors.
Tyra Biosciences Q3 net loss widens to $12.5M; CFO van den Boom to step down, Fuhrman appointed
Net loss of $12.5M in Q3 2022 vs $6.6M a year ago; cash and equivalents $263.2M.
Tyra Biosciences enters $150M ATM equity offering facility with Virtu Americas
Company may sell up to $150M of common stock at prevailing market prices through Agent Virtu Americas LLC.
Tyra Biosciences reports Q2 net loss of $15.1M; FDA clears IND for TYRA-300
Q2 2022 net loss $15.1M vs $5.5M in Q2 2021; R&D expense $12.0M vs $4.4M.
Todd Harris, Nina Kjellson, and Siddarth Subramony elected as Class I directors with ~30.05M votes each; broker non-votes ~1.09M.
Tyra Biosciences Q1 net loss $14.8M; cash $292.5M; IND filings on track for 2022
Net loss of $14.8M in Q1 2022 vs $4.2M in Q1 2021, driven by higher R&D and G&A expenses.
Tyra Biosciences Q4 net loss $9.9M, cash $302.2M; IND filings on track
Q4 2021 net loss $9.9M vs $3.7M; full-year net loss $26.3M vs $9.3M.
Tyra Biosciences Q3 net loss $6.6M; cash $312.8M post-$198.7M IPO
Cash and equivalents $312.8M as of Sep 30, 2021, up from $15.2M at Dec 31, 2020.
Tyra Biosciences closes IPO of 12.42M shares at $16, raising $198.7M gross proceeds
IPO of 12.42M shares (includes full underwriter option) at $16.00/share closed on Sep 17, 2021.
the Board appointed Adele M. Gulfo as a director of the Board, filling the Class I vacancy on the Board resulting from Ms. Kjellson’s resignation.
Nina Kjellson resigned from the Board and the Compensation Committee of the Board effective as of January 29, 2025
On October 24, 2024, Siddarth Subramony, Ph.D. resigned from the Board of Directors (the Board) of Tyra Biosciences, Inc. (Tyra or the Company) and the Compensation Committee of the Board (the Compensation Committee) effective immediately.
appointed Susan Moran, M.D., M.S.C.E. and S. Michael Rothenberg, M.D., Ph.D. as directors.
appointed Susan Moran, M.D., M.S.C.E. and S. Michael Rothenberg, M.D., Ph.D. as directors.
Isan Chen, M.D. resigned from the Board and the Compensation Committee of the Board effective as of May 7, 2024.
On October 28, 2022, Esther van den Boom, the Chief Financial Officer of Tyra Biosciences, Inc. (the “Company”), informed the Company of her intent to resign as the Company’s Chief Financial Officer, effective December 31, 2022.
On November 1, 2022, the Board of Directors of the Company (the “Board”) appointed Alan Fuhrman to replace Ms. van den Boom as the Company’s Chief Financial Officer, effective January 1, 2023.
Max materiality 0.85 · Median 0.60 · Most common event earnings